Darbepoetin Alfa

Near Add Your Location

Accepting patients

A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
Learn more
  • Erythropoiesis-Stimulating Agent (ESA)
  • Monoclonal Antibody
  • Red Blood Cell Stimulant
  • Phase 1/2
  • Has results